The C-Suite Speaks
In an exclusive interview, Seth Lederman, CEO of New York-based Tonix Pharmaceuticals, talks about the company’s R&D rollercoaster ride and how it plans to keep its lead asset on track for approval as a treatment for post-traumatic stress disorder.
Gene therapy’s promise depends on the ecosystem now being built to deliver real product to patients – safely and at quantities that match the soaring expectations fed by the curative potential of the science. To assess the state of play, In Vivo talks to the man who leads the team responsible for bringing forward the first US-approved gene therapy to treat an incurable, inherited genetic condition: John Furey, chief operating officer of Spark Therapeutics.
Latest From C-Suite Speaks
Aduro Biotech announced a “strategic reset” in January 2019 that will see the Californian company center around two core pipeline programs, cut its headcount and focus on pharma partnerships. Stephen Isaacs, chair, president and CEO of the company, speaks to In Vivo about his vision for Aduro as the 2020s approach, and the challenges a smaller biotech faces when balancing multiple big pharma agreements.
Ascensia is pushing back the borders of diabetes control, using its legacy BGM technology as a business platform to move into CGM en route to becoming a one-stop-shop for diabetes management solutions. A significant step toward these goals was taken in January, when the Swiss group completed a key China deal with a local CGM innovator, as chief marketing and strategy officer Martin Lange explained to In Vivo.
Industry executives, consultants and analysts speculate on what they believe the big themes, trends and events will be this year.
The health care world once viewed barriers to access in terms of reimbursement and legislation. While these are still prevalent in the conversation, there is a greater focus on nuanced barriers – such as how treatments impact quality of life, convenience for patients, route of administration and side effects.
Cell and gene therapy represent a transformative advance in drug delivery and outcomes, with implications equally as important to human progress as the digital revolution that began three decades ago.In Vivo speaks with a key player in this evolving field, GE Healthcare’s strategy manager for cell and gene therapy and board member of the Alliance for Regenerative Medicine, Phil Vanek, PhD.
In 1988 Len Schleifer took a talented scientist, George Yancopoulos, out to dinner to persuade the immunologist to join his newly formed company. Thirty years, six drug approvals and many arguments later, pharma’s most famous friendship is now looking to change the way allergies are treated.
If strategic planning is a necessary hedge against the drawn-out, asset-draining product cycles of today’s big pharma enterprise, then what is the secret of doing it well? In Vivo looks for answers in a conversation with Novartis strategy lead Stephen Moran.
Healios, a Japanese regenerative medicine bioventure, expects to continue benefiting from a supportive regulatory environment in Japan as it progresses three clinical assets toward approval in the next few years, says CEO Dr. Hardy Kagimoto in an exclusive interview.
The contract drug delivery industry is facing disruptive influences from an evolving client base, the increase in biologics manufacturing and specialty pharma needs. In Vivo speaks to Catalent’s vice president of strategy, Cornell Stamoran, about the evolution of the industry and the continuous search for efficiency.
Boston Scientific Corp. has been back on the M&A trail in a big way in 2018, with a succession of strategic additions of various sizes that all have potential patient and shareholder impact across – and beyond – its established divisions. Chief medical officer of 18 months Ian Meredith explains the thought processes driving this policy, and the added dimension a CMO can bring to the overall question of strategy.
Drug delivery technology specialist Consort Medical has capitalized on device respiratory expertise for 50 years, but a renewed focus on strategic expansion has seen it make an IP play, move into the pharma side and target other delivery formats for global pharma industry customers. Its enhanced capabilities will keep rivals on their toes.
Lars Rebien Sørensen scrutinizes the pharmaceutical industry and shares with In Vivo his vision for the future of the Novo Nordisk Foundation. With 16 years as CEO of Novo Nordisk under his belt, as well as many more years in leadership roles at the Danish company, Sørensen reflects on the past and gives his predictions for the future of the innovative drug development sector.
The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.
Experiments are underway to solve pharma’s well-documented R&D productivity crisis. The industry is no longer focused only on buying new drugs via M&A, or on outsourcing discovery. Companies are also building new channels through which to access innovation, setting up different kinds of partnerships, and using new kinds of data. The shift involves re-thinking pharma’s place in healthcare.
Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.
Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.
The threat of cyberattacks on biopharma’s extensive information assets is moving to the top of the list of business risks confronting senior C-suite management. In Vivo’s Roundtable panel of leading biopharma CISOs reviews what to do and what it will take to convince others in senior management to buy into a challenge that still remains largely below the surface.
The ups, downs – and nearly outs – of ASX-listed health technologies manufacturer and distributor Admedus have made compelling reading in the past two years, but CEO Wayne Paterson has brought a competitive edge to a company that was lacking focus. Now he is looking to raise the bar again, aiming to use the company's proprietary Adapt patch technology in the TAVR space, while also pressing on with strategic plans for the therapeutic vaccines portfolio and adding scale.
Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Flex Health Solutions' role in the medtech space is helping other companies develop superior products for the broadest market appeal. Its ability to source ideas for medical design from other parts of its $24 billion business means it is already leveraging the Fourth Industrial Revolution, just at the point that the industry is undergoing dramatic change.
When Olympus Corp. re-entered the M&A arena after five years of "back to the basics," it was via the purchase of a company that meets every parameter of its requirements. Nacho Abia says that OR integrator Image Stream Medical should also help the Japanese multinational stay on course to meet value-based – and ambitious mid-term sales – targets.
Becton Dickinson President, Chairman and CEO Vincent Forlenza speaks to IN VIVO about the business prospects at Becton Dickinson as it integrates its major acquisition, CareFusion, and oversees a major internal group restructuring, and about his role as the current chairman of AdvaMed.
Cardiovascular Research Foundation leaders Jack Lewin, Juan Granada, and Ori Ben-Yehuda talk to IN VIVO about the state of medtech innovation and health care in the US.
Renal denervation is arguably the hottest new device technology to come along in years, with applications in a variety of chronic diseases including hypertension and diabetes, to name just two. Yet just over a decade ago, most people laughed off the concept, and they might still be laughing were it not for the efforts of a novel device development company called Coridea.
In a wide-ranging interview conducted at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business, of the key late-stage assets that will carry the company into the next decade, and of business development priorities in the post-Nycomed era.
After emerging from the DOJ settlements, the leading pure-play orthopedics company is emphasizing – and redefining – innovation to drive growth. Zimmer CEO David Dvorak talks to IN VIVO about his company’s commitment to innovation, and how the very notion of innovation is changing.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.